Deciphering female’s SEx hormones - MIcrobiota interactions during a menstrual C...
Deciphering female’s SEx hormones - MIcrobiota interactions during a menstrual CYCLE for an efficient personalized medicine in cardiometabolic disorders
Cardiometabolic disorders (CMD), a group of conditions that include cardiovascular diseases, type 2 diabetes and metabolic syndrome, are characterised by dysfunction of glycaemic and/or lipid metabolism. Clinical manifestations, s...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto SEMICYCLE
Duración del proyecto: 61 meses
Fecha Inicio: 2023-03-23
Fecha Fin: 2028-04-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Cardiometabolic disorders (CMD), a group of conditions that include cardiovascular diseases, type 2 diabetes and metabolic syndrome, are characterised by dysfunction of glycaemic and/or lipid metabolism. Clinical manifestations, severity and progression are different between sexes, the underlying mechanisms of which are largely unknown. The poorer prognosis in women globally calls for an urgent need for better women’s tailored prevention and treatment strategies. Still, for an efficient personalised strategy, female-specific mechanisms have to be identified. The SEMICYCLE project will systematically investigate female’s sex hormones-microbiota interactions to unravel female-specific microbiota features regulating glycaemic and lipid metabolism in women during homeostasis and diseases. Findings of this research project will pinpoint key mechanisms useful to improve current prevention and diagnostic tools as well as therapeutic options of CMD. SEMICYCLE will follow up 300 healthy women during one menstrual cycle and longitudinal cross-omics data (five layers of information from host genome, gut microbiome, gut metabolome, vaginal microbiome, plasma proteome) will be generated, analysed and integrated with female sex hormones variations, lifestyle and diet, glycaemic and lipid phenotypes using state-of-the-art methodologies and computational approaches. Subsequently, mechanisms identified during homeostasis will be investigated for association with CMD onset and progression, using already existing cohorts totalling more than 10,000 samples. This research is based on my expertise and that of my research group in generating and analysing omics data in large data sets. Findings will reveal previously unknown microbiota regulators of CMD in women thus offering alternative routes for prevention, diagnosis and treatments in women, a necessary step for an efficient personalised medicine.